Chief Medical Officer – Oncology Radiopharmaceuticals

About the role

Lead the transition of an emerging biotechnology company from pre‑clinical research to first‑in‑human oncology studies, shaping a global theranostics strategy and building the clinical function.

Key responsibilities

• Define and drive the overall clinical development strategy for oncology‑focused radiopharmaceutical programmes, from first‑in‑human to proof‑of‑concept and registration pathways.
• Design early‑phase studies, including protocol development, dose‑escalation, and expansion cohorts, and oversee investigator selection, site strategy and CRO management.
• Integrate safety, PK/PD, imaging, biodistribution and dosimetry data to inform programme decisions and establish a translational medicine framework linking pre‑clinical findings with clinical evidence.
• Represent the company with health authorities and regulatory agencies, leading scientific advice, submission activities and safety governance.
• Build and scale core clinical functions such as medical monitoring, safety, biometrics and medical affairs, while maintaining relationships with key opinion leaders worldwide.

Required profile

• Medical Doctor (MD) qualification with >10 years of biotech/pharma clinical development experience.
• Proven track record in oncology drug development, especially early‑phase, first‑in‑human and dose‑escalation studies.
• Deep understanding of clinical safety, GCP, PK/PD, biomarkers and regulatory requirements.
• Experience interacting directly with health authorities and contributing to regulatory submissions.
• Ability to work strategically while remaining hands‑on in a fast‑growing organization.

Required skills

• Clinical safety expertise
• Good Clinical Practice (GCP) knowledge
• Pharmacokinetics/Pharmacodynamics (PK/PD) principles
• Biomarker integration
• Regulatory submission experience

What we offer

• Executive leadership role at a transformational biotech company.
• Ownership of global clinical strategy and responsibility for taking innovative oncology assets into human studies.
• Opportunity to shape programme direction and organisational design from the outset.
• Visibility with investors, regulators, academic leaders and potential partners.
• Chance to build a clinical development organisation and leave a lasting impact.